Insmed reported $-261.35M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Novartis USD 4.48B 343M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025